SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-01-21 2025-01-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 21, 2025

 

 

SOLENO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36593   77-0523891

(State or other jurisdiction

of incorporation)

  

(Commission

File No.)

  

(IRS Employer

Identification Number)

100 Marine Pkwy, Suite 400

Redwood City, CA 94065

(Address of principal executive offices)

(650) 213-8444

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbols

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   SLNO   NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) Named Executive Officer Compensation

On January 21, 2025, the Board of Directors of Soleno Therapeutics, Inc., (the “Company”) following a review of the Company’s executive compensation program by its Compensation Committee and upon its recommendations, approved certain increases to the base salaries for fiscal year 2025, the payment of cash bonuses for fiscal year 2024 and certain equity awards for the Company’s named executive officers as follows:

 

Name and Principal Position    Fiscal Year 2025 Annual
Base Salary(1)		      Fiscal Year 2024 Cash
Bonus Award		      Options(2)      Restricted Stock
Awards(3)		  

Anish Bhatnagar

Chief Executive Officer

    $ 739,000      $ 403,200        115,600        53,900  

James Mackaness

Chief Financial Officer

    $ 511,000      $ 193,200        31,000        14,500  

Patricia Hirano

Senior Vice President of Regulatory Affairs

    $ 432,000      $ 137,812        13,800        6,400  

 

(1)

Effective as of January 1, 2025.

(2)

One forty-eighth (1/48th) of the shares subject to the Option shall vest on the first anniversary of January 1, 2025 (the Vesting Commencement Date), and one forty-eighth (1/48th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

(3)

Twenty-five percent (25%) of the RSU shares shall vest on each annual anniversary of December 15, 2024.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SOLENO THERAPEUTICS, INC.
Date: January 24, 2025    
    By:  

/s/ Anish Bhatnagar

      Anish Bhatnagar
      Chief Executive Officer

 

3

v3.24.4
Document and Entity Information
Jan. 21, 2025
Cover [Abstract]  
Entity Registrant Name SOLENO THERAPEUTICS INC
Amendment Flag false
Entity Central Index Key 0001484565
Document Type 8-K
Document Period End Date Jan. 21, 2025
Entity Incorporation State Country Code DE
Entity File Number 001-36593
Entity Tax Identification Number 77-0523891
Entity Address, Address Line One 100 Marine Pkwy
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code (650)
Local Phone Number 213-8444
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol SLNO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Soleno Therapeutics (NASDAQ:SLNO)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Soleno Therapeutics 차트를 더 보려면 여기를 클릭.
Soleno Therapeutics (NASDAQ:SLNO)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Soleno Therapeutics 차트를 더 보려면 여기를 클릭.